A Phase I, Open-Label, Single-Dose, Adaptive (S)-(-)-[18F]Fluspidine and [18F]Fallypride Positron Emission Tomography Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

Trial Profile

A Phase I, Open-Label, Single-Dose, Adaptive (S)-(-)-[18F]Fluspidine and [18F]Fallypride Positron Emission Tomography Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Pridopidine (Primary)
  • Indications Huntington's disease
  • Focus Pharmacodynamics
  • Sponsors Teva Branded Pharmaceutical Products R&D
  • Most Recent Events

    • 02 May 2018 Status changed from recruiting to completed.
    • 22 Oct 2017 Planned End Date changed from 21 Dec 2017 to 24 Jan 2018.
    • 11 Oct 2017 Planned End Date changed from 7 Oct 2017 to 21 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top